Longitudinal lipidomic analyses in patients undergoing therapeutic plasma exchange with albumin replacement as a treatment for Alzheimer’s disease

Differences in ceramides, glycerides, phospholipids, cholesterol esters and fatty acids (FA) lipid subclasses have been reported between Alzheimer’s disease (AD) patients and healthy subjects (Liu et al. Transl Psychiatry 2021;11:344). The AMBAR phase 2b/3 trial is a therapeutic approach for mild‐moderate AD patients (MMSE:18‐26) based on a 14‐month program comprising 18 plasma exchange procedures with albumin replacement (PE‐Alb) to remove neurotoxic Aβ and other pathological substances from plasma, thus slowing AD progression (Boada et al. Alzheimers Dement 2020;16:1412). The aim of this study was to assess PE‐Alb effects on lipidomics across the AMBAR study.